CA3013770A1 - Bacteries modifiees pour traiter des maladies pour lesquelles une diminution de l'inflammation intestinale et/ou une plus grande impermeabilite de la muqueuse intestinale s'averent benefiques - Google Patents

Bacteries modifiees pour traiter des maladies pour lesquelles une diminution de l'inflammation intestinale et/ou une plus grande impermeabilite de la muqueuse intestinale s'averent benefiques Download PDF

Info

Publication number
CA3013770A1
CA3013770A1 CA3013770A CA3013770A CA3013770A1 CA 3013770 A1 CA3013770 A1 CA 3013770A1 CA 3013770 A CA3013770 A CA 3013770A CA 3013770 A CA3013770 A CA 3013770A CA 3013770 A1 CA3013770 A1 CA 3013770A1
Authority
CA
Canada
Prior art keywords
gene
bacterium
promoter
disease
butyrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3013770A
Other languages
English (en)
Inventor
Paul F. Miller
Vincent M. Isabella
Jonathan W. Kotula
Dean Falb
Adam B. FISHER
Yves Millet
Ning Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synlogic Operating Co Inc
Original Assignee
Synlogic Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/020530 external-priority patent/WO2016141108A1/fr
Priority claimed from PCT/US2016/032565 external-priority patent/WO2016183532A1/fr
Priority claimed from PCT/US2016/039444 external-priority patent/WO2016210384A2/fr
Priority claimed from PCT/US2016/050836 external-priority patent/WO2017074566A1/fr
Priority claimed from US15/260,319 external-priority patent/US11384359B2/en
Priority claimed from PCT/US2016/069052 external-priority patent/WO2017123418A1/fr
Application filed by Synlogic Operating Co Inc filed Critical Synlogic Operating Co Inc
Publication of CA3013770A1 publication Critical patent/CA3013770A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/52—Propionic acid; Butyric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Des bactéries génétiquement modifiées, des compositions pharmaceutiques les comprenant ainsi que des méthodes de traitement ou de prévention de troubles auto-immuns, de l'inhibition de mécanismes inflammatoires dans l'intestin, et/ou de renforcement de la fonction de barrière de la muqueuse intestinale sont divulguées.
CA3013770A 2016-02-04 2017-02-03 Bacteries modifiees pour traiter des maladies pour lesquelles une diminution de l'inflammation intestinale et/ou une plus grande impermeabilite de la muqueuse intestinale s'averent benefiques Pending CA3013770A1 (fr)

Applications Claiming Priority (35)

Application Number Priority Date Filing Date Title
US201662291468P 2016-02-04 2016-02-04
US201662291461P 2016-02-04 2016-02-04
US201662291470P 2016-02-04 2016-02-04
US62/291,468 2016-02-04
US62/291,470 2016-02-04
US62/291,461 2016-02-04
PCT/US2016/020530 WO2016141108A1 (fr) 2015-03-02 2016-03-02 Bactéries modifiées pour traiter des maladies pour lesquelles une diminution de l'inflammation intestinale et/ou une plus grande imperméabilité de la muqueuse intestinale s'avèrent bénéfiques
USPCT/US2016/020530 2016-03-02
USPCT/US2016/032565 2016-05-13
PCT/US2016/032565 WO2016183532A1 (fr) 2015-05-13 2016-05-13 Bactéries modifiées pour traiter une maladie ou un trouble
US201662347508P 2016-06-08 2016-06-08
US201662347576P 2016-06-08 2016-06-08
US62/347,508 2016-06-08
US62/347,576 2016-06-08
US201662348620P 2016-06-10 2016-06-10
US62/348,620 2016-06-10
US201662354682P 2016-06-24 2016-06-24
PCT/US2016/039444 WO2016210384A2 (fr) 2015-06-25 2016-06-24 Bactéries manipulées pour traiter des maladies métaboliques
USPCT/US2016/039444 2016-06-24
US62/354,682 2016-06-24
US201662362954P 2016-07-15 2016-07-15
US62/362,954 2016-07-15
US201662385235P 2016-09-08 2016-09-08
US62/385,235 2016-09-08
US15/260,319 2016-09-08
PCT/US2016/050836 WO2017074566A1 (fr) 2015-10-30 2016-09-08 Bactéries modifiées pour traiter des maladies pour lesquelles une diminution de l'inflammation intestinale et/ou une plus grande imperméabilité de la muqueuse intestinale s'avèrent bénéfiques
USPCT/US2016/050836 2016-09-08
US15/260,319 US11384359B2 (en) 2014-12-22 2016-09-08 Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
US201662423170P 2016-11-16 2016-11-16
US62/423,170 2016-11-16
US201662439871P 2016-12-28 2016-12-28
US62/439,871 2016-12-28
USPCT/US2016/069052 2016-12-28
PCT/US2016/069052 WO2017123418A1 (fr) 2016-01-11 2016-12-28 Bactéries modifiées pour traiter des maladies métaboliques
PCT/US2017/016603 WO2017136792A2 (fr) 2016-02-04 2017-02-03 Bactéries modifiées pour traiter des maladies pour lesquelles une diminution de l'inflammation intestinale et/ou une plus grande imperméabilité de la muqueuse intestinale s'avèrent bénéfiques

Publications (1)

Publication Number Publication Date
CA3013770A1 true CA3013770A1 (fr) 2017-08-10

Family

ID=59500293

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3013770A Pending CA3013770A1 (fr) 2016-02-04 2017-02-03 Bacteries modifiees pour traiter des maladies pour lesquelles une diminution de l'inflammation intestinale et/ou une plus grande impermeabilite de la muqueuse intestinale s'averent benefiques

Country Status (4)

Country Link
EP (1) EP3411051A2 (fr)
AU (1) AU2017213646A1 (fr)
CA (1) CA3013770A1 (fr)
WO (1) WO2017136792A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016210384A2 (fr) 2015-06-25 2016-12-29 Synlogic, Inc. Bactéries manipulées pour traiter des maladies métaboliques
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
WO2017019895A1 (fr) 2015-07-30 2017-02-02 President And Fellows Of Harvard College Évolution des talen
WO2019241649A1 (fr) 2018-06-14 2019-12-19 President And Fellows Of Harvard College Évolution de cytidine désaminases
WO2020223345A1 (fr) 2019-04-29 2020-11-05 Antipov Eugene Dénombrement de micro-organismes génétiquement modifiés par des techniques de comptage de cellules vivantes
WO2021242897A1 (fr) * 2020-05-26 2021-12-02 Synlogic Operating Company, Inc. Bactéries recombinées pour la production d'acide indole-3-acétique (iaa) et leurs utilisations
US20230364162A1 (en) * 2020-09-28 2023-11-16 The Regents Of The University Of Michigan Methods and compositions for intestinal inflammation
CN112458033B (zh) * 2020-11-16 2023-01-24 四川农业大学 减毒鼠伤寒沙门菌及其构建方法与应用
WO2022120028A2 (fr) 2020-12-02 2022-06-09 Synlogic Operating Company, Inc. Micro-organismes modifiés
WO2023010050A1 (fr) * 2021-07-28 2023-02-02 The Broad Institute, Inc. Procédés d'évolution continue assistée par phage périplasmique
EP4162946A1 (fr) * 2021-10-05 2023-04-12 Institut national de recherche pour l'agriculture, l'alimentation et l'environnement Kynurénine-aminotransférase et produits associés pour le traitement de maladies intestines inflammatoires
CN114369146B (zh) * 2022-01-14 2023-05-23 上海交通大学医学院附属仁济医院 一种阿克曼氏菌Amuc_2172蛋白及其制备方法和用途
EP4295859A1 (fr) * 2022-06-20 2023-12-27 Institut national de recherche pour l'agriculture, l'alimentation et l'environnement Kynurénine-aminotransférase et produits associés pour le traitement des maladies arthritiques

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
EP1034787A1 (fr) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Souches de lactobacillus capables de prévenir la diarrhée causée des bactéries pathogènes
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
WO2008143704A2 (fr) * 2006-12-01 2008-11-27 Gevo, Inc. Microorganismes élaborés pour produire du n-butanol et procédés correspondants
EP2655624B1 (fr) 2010-12-23 2017-11-29 Biogen MA Inc. Peptides coupleurs et polypeptides les comportant
US20160206666A1 (en) * 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
BR112017018656B1 (pt) * 2015-03-02 2021-11-30 Synlogic, Inc Bactéria geneticamente modificada, composição farmaceuticamente aceitável compreendendo a dita bactéria e uso da dita composição para tratar ou prevenir uma doença ou condição associada à inflamação intestinal e/ou função da barreira intestinal comprometida

Also Published As

Publication number Publication date
WO2017136792A3 (fr) 2017-09-08
WO2017136792A8 (fr) 2017-09-28
EP3411051A2 (fr) 2018-12-12
AU2017213646A1 (en) 2018-08-23
WO2017136792A2 (fr) 2017-08-10

Similar Documents

Publication Publication Date Title
US20230043588A1 (en) Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
CA3013770A1 (fr) Bacteries modifiees pour traiter des maladies pour lesquelles une diminution de l'inflammation intestinale et/ou une plus grande impermeabilite de la muqueuse intestinale s'averent benefiques
US11384359B2 (en) Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
US20240110192A1 (en) Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
US11685925B2 (en) Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
US11896627B2 (en) Bacteria engineered to treat metabolic diseases
US20190010506A1 (en) Bacteria engineered to treat metabolic diseases
WO2017123418A1 (fr) Bactéries modifiées pour traiter des maladies métaboliques
WO2017139697A9 (fr) Bactéries modifiées en vue du traitement de maladies associées à l'hyperammoniémie
WO2016210373A2 (fr) Bactéries recombinantes modifiées pour la biosécurité, compositions pharmaceutiques, et leurs procédés d'utilisation
WO2017136795A1 (fr) Bactéries modifiées pour traiter des maladies associées au metabolisme du tryptophane
JP2018532412A5 (fr)
WO2017123676A9 (fr) Bactéries recombinées modifiées pour traiter des maladies et des troubles associés à un métabolisme des acides aminés et leurs méthodes d'utilisation
WO2017139708A1 (fr) Bactéries génétiquement modifiées pour traiter la stéatohépatite non alcoolique (shna)
WO2017123610A2 (fr) Bactéries modifiées pour détoxifier les molécules délétères
US20210161976A1 (en) Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
US20230174926A1 (en) Bacteria engineered to treat disorders involving the catabolism of leucine
EP3313371A2 (fr) Bactéries manipulées pour traiter des maladies métaboliques

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220202

EEER Examination request

Effective date: 20220202

EEER Examination request

Effective date: 20220202

EEER Examination request

Effective date: 20220202